Biopsy techniques & accuracy

Accuracy by Biopsy Type: — A Comparison

Different biopsy techniques are not interchangeable. Each gives a different amount of tissue and a different level of diagnostic confidence — and knowing what yours can and cannot tell you is a reasonable thing to understand.

Medically reviewed by Dr. Mohammed Imaduddin, Surgical Oncologist, MBBS · MS (General Surgery) · M.Ch (Surgical Oncology) · Last reviewed September 2026

More tissue, more confidence — Techniques that remove larger samples give the pathologist more to work with and reduce the chance that the abnormal area was missed.
Sampling is not the whole lesion — Any needle biopsy tests only what it reaches. A clear result means the sample was clear — not necessarily the entire lesion.
FNA has real limits — Fine needle aspiration provides cells, not tissue structure, which is enough for some diagnoses and not others.
The choice was deliberate — The technique your doctor used was matched to where your lesion is and what the result needs to show.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Excisional biopsy — removing an entire lesion — gives the most diagnostic information and is the reference standard for several cancer types. Core needle biopsy is reliable for most solid tumours. Fine needle aspiration carries a higher rate of inconclusive results. Liquid biopsy is best used alongside tissue testing, not instead of it.

What does each biopsy technique actually do?

Excisional biopsy: The entire lesion is removed surgically. The pathologist examines the complete sample including its edges. This is the reference standard for melanoma and some lymphomas because there is no part left unsampled.
Incisional biopsy: A portion of a larger lesion is removed. Used when the lesion is too large to excise in one step. Diagnostic confidence depends on whether the sampled area represents the whole.
Core needle biopsy: A hollow needle removes a cylinder of tissue, preserving the relationships between cells. This tissue architecture makes it more informative than FNA, and it is the standard approach for breast lumps, prostate assessment and many soft-tissue masses.
Fine needle aspiration (FNA): A thin needle withdraws individual cells rather than a tissue core. Adequate for confirming cancer in accessible lymph nodes or thyroid nodules in many situations; insufficient for lymphoma subtyping or cancers where receptor testing requires intact tissue.
Liquid biopsy: Tests circulating tumour DNA in a blood sample — no tissue procedure required. ESMO and ASCO position it as a complement to tissue biopsy, not a replacement, because sensitivity for early-stage disease is lower. Most useful for monitoring treatment response and detecting resistance mutations after diagnosis.
Bone marrow biopsy: A core of marrow is removed from the hip bone. Standard for diagnosing and staging blood cancers such as leukaemia, lymphoma and myeloma, where marrow involvement cannot be determined from a blood test alone.

Which biopsy type gives the most reliable result?

Excisional biopsy gives the highest confidence because the entire lesion is examined. Core needle biopsy is reliable for most solid tumours — NCCN and ASCO guidance supports it as the standard first step for breast and prostate cancer because concordance with surgical findings is consistently high.

FNA is adequate where only cell identification is needed, such as confirming a recurrence in an accessible lymph node. It is not adequate where treatment depends on knowing the exact subtype or where receptor testing requires intact tissue.

Liquid biopsy cannot yet rule out cancer the way a tissue biopsy approaches doing. A negative liquid biopsy in early-stage disease does not carry the same diagnostic weight as a negative tissue result.

Can a biopsy result be wrong?

A biopsy reports only on the tissue sampled. If the needle did not reach the abnormal area — because the lesion is uneven internally, the target moved, or the sample came from the edge — the result reflects the sampled tissue, not the whole lesion. This is called sampling error.

A result that contradicts the clinical picture is a recognised pattern, not an unusual one. Your oncologist is trained to weigh the biopsy result alongside imaging and symptoms together, not to accept it in isolation when the two conflict.

If your result and your symptoms feel like they do not match, say so to your treating team. That conversation is expected and appropriate.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What happens when a result does not match the clinical picture?

The team weighs both together
Your oncologist reviews the biopsy result against imaging, symptoms and examination. A benign biopsy with a highly suspicious scan is a known mismatch — not an automatic reassurance.
A second pathology opinion may be requested
Your tissue block can be sent to a specialist pathologist without a new procedure. This is standard practice before an unexpected diagnosis is accepted or an unusual treatment decision is made.
A repeat or different biopsy is considered
If the first sample may have missed the area of concern, a repeat — often with imaging guidance or a technique that takes more tissue — may be recommended.
Short-interval imaging may be used
A scan in weeks rather than months can show whether a lesion is stable, growing or resolving. A growing lesion after a benign biopsy almost always leads to further sampling.

Why did your doctor choose the technique they used?

The technique is matched to three things: where the lesion is, what the result needs to show, and what risks the procedure carries for you.

A small, accessible lump near the surface may be excised entirely — diagnosis and treatment in one step. A deep lesion near a blood vessel may be sampled by a guided core needle, because imaging guidance makes the procedure safer than open surgery.

The choice is not about which technique is best in the abstract. It is about which gives enough information for the next decision with the least risk to you.

Did you know?

When a biopsy result is unexpected or will guide a major treatment decision, sending the tissue block for a second pathology opinion is a standard step — not an unusual request.

ASCO guidance supports second-opinion pathology review as part of good oncological practice, particularly before starting systemic treatment.

Source: ASCO Clinical Practice Guidelines

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

False Negatives & Accuracy

Breast Markers: ER, PR, HER2, Ki-67

IHC Markers Explained

Inadequate, Inconclusive & Repeat Biopsy

Labs, Slides, Blocks & Second Opinions

Molecular & Genomic Testing

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

Is a core needle biopsy as accurate as removing the whole lump?

For most cancers, yes. Core needle biopsy results closely match what surgical excision would show, and NCCN and ASCO support it as the standard first step for breast and prostate cancer on that basis. The situations where excision is preferred are where the lesion is small enough to remove safely in one step, where the subtype cannot be reliably determined from a needle sample, or where the needle result was inconclusive.

My FNA came back benign but I am still worried. Should I ask for more testing?

It is reasonable to raise this with your doctor. FNA has a higher rate of inconclusive or insufficient results than core needle biopsy, and some cancers — including certain lymphomas — cannot be reliably classified from FNA alone. If the lesion was suspicious on imaging, or if the FNA was reported as atypical or insufficient rather than clearly benign, those are specific points to bring up. Your concern is clinically relevant information, not just anxiety.

Can a liquid biopsy replace a tissue biopsy?

Not for most initial diagnoses at this stage. ESMO and ASCO position liquid biopsy as a complement to tissue testing because its sensitivity in early-stage disease is lower than tissue-based methods. It is most useful when repeat tissue sampling is difficult or risky, when monitoring treatment response, and for detecting resistance mutations. If a liquid biopsy is being recommended instead of tissue testing, ask your team specifically what question it is answering and why tissue was not preferred.

What does 'inconclusive' or 'insufficient sample' mean on my biopsy report?

It means the laboratory did not receive enough cells or tissue to give a definitive answer — a technical finding about the sample, not a finding about your cancer. It commonly leads to a repeat procedure using a larger needle or with imaging guidance to target the area more precisely. Ask your team what the next step is and how soon it can be arranged. Waiting without a plan after an inconclusive result is not the right outcome.

Does where exactly the needle went within the tumour affect the result?

Yes. Many tumours are not uniform — different areas can have different molecular profiles and different degrees of abnormality. This is called intratumoural heterogeneity, and it is a genuine source of sampling error rather than a failure of technique. It is why a result that contradicts the clinical picture prompts further sampling rather than automatic reassurance, and why treatment decisions that depend on specific markers may require testing of more than one area.

Can I ask for my biopsy slides to be reviewed at another hospital?

Yes, and this is a routine request. Your tissue block and slides remain available after the procedure and can be sent to another pathologist or specialist centre without a new biopsy. You are entitled to ask for this — particularly before starting chemotherapy, immunotherapy or a targeted treatment, or if you are seeking a second opinion on your overall diagnosis. Ask either your treating team or the pathology department at the hospital where the biopsy was done.

Full index